17 completed, 5 terminated, 3 recruiting, 2 not yet recruiting. 14 Phase 3, 8 Phase 2, 5 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 11, Terminated 3 |
| Phase 2 | 8 | Completed 5, Withdrawn 2, Terminated 1 |
| Phase 4 | 5 | Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow fremanezumab: new trials by email Literature Review of fremanezumab trials Research Report on fremanezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution, Placebo - Acute Mountain Sickness | Phase 4 | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | 30 | 2027-06-01 | 2026-07-01 |
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity Fremanezumab - Migraine | Completed | Fondazione Policlinico Universitario Campus Bio-Medico | 308 | 2024-10-03 | 2026-09-02 | |
| Fremanezumab for the Prevention of Menstrually-related Migraine Attacks Fremanezumab - Menstrual Migraine | Recruiting | Insel Gruppe AG, University Hospital Bern | 120 | 2024-04-09 | 2024-10-26 | |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 Fremanezumab, Placebo - Migraine, Menstrual Migraine | Phase 4 | Completed | Brigham and Women's Hospital | 15 | 2024-03-01 | 2026-08-26 |
| COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL) - Chronic Migraine, Headache | Phase 4 | Unknown | Chicago Headache Center & Research Institute | 50 | 2023-01-26 | 2024-08-20 |
| Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study Erenumab, Fremanezumab, Galcanezumab - Migraine, Migraine With Aura | Unknown | Austrian Migraine Registry Collaboration | 1500 | 2022-10-01 | 2022-10-20 | |
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 365 | 2022-09-30 | 2025-11-26 |
| Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution - Migraine Disorders | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 1000 | 2022-04-20 | 2026-06-22 | |
| Real World Effectiveness of Eptinezumab in Participants With Migraine Eptinezumab, Erenumab, Onabotulinumtoxin-A - Migraine | Phase 4 | Terminated | H. Lundbeck A/S | 32 | 2022-03-04 | 2024-05-29 |
| Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Fremanezumab, Placebo - Cadasil, Migraine | Phase 2 | Withdrawn | Mayo Clinic | 2021-12-01 | 2022-02-28 | |
| A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome fremanezumab - Interstitial Cystitis | Phase 2 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2020-10-15 | 2021-11-09 | |
| CGRP Inhibition, Autonomic Function, and Migraine Erenumab, Galcanezumab, Fremanezumab - Episodic Migraine, Chronic Migraine | Recruiting | Medical University of Vienna | 120 | 2020-10-01 | 2024-12-10 | |
| A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 292 | 2020-09-24 | 2025-12-19 |
| A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Fremanezumab - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 499 | 2020-09-16 | 2026-07-24 |
| A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 235 | 2020-07-15 | 2026-06-22 |
| A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder Fremanezumab, Placebo - Migraine, Major Depressive Disorder | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 353 | 2019-09-13 | 2023-10-02 |
| A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia Fremanezumab, Placebo - Fibromyalgia | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 189 | 2019-07-31 | 2023-03-30 |
| Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine TEV-48125, TEV-48125 or placebo, Placebo - Migraine | Phase 2 / Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 357 | 2017-12-19 | 2021-07-29 |
Showing 20 of 33. Sign in to see all of them.
Migraine Disorders (22) · Cluster Headache (3) · Cystitis, Interstitial (2) · Headache (2) · Altitude Sickness (1) · CADASIL (1) · Cranial Nerve Injuries (1) · Depressive Disorder, Major (1) · Fibromyalgia (1) · Migraine with Aura (1) · Migraine without Aura (1) · Oropharyngeal Neoplasms (1) · Post-Traumatic Headache (1) · Urinary Bladder, Overactive (1)
Teva Branded Pharmaceutical Products R&D, Inc. (16) · Otsuka Pharmaceutical Co., Ltd. (4) · Insel Gruppe AG, University Hospital Bern (2) · Teva Branded Pharmaceutical Products R&D LLC (2) · Austrian Migraine Registry Collaboration (1) · Brigham and Women's Hospital (1) · Chicago Headache Center & Research Institute (1) · Fondazione Policlinico Universitario Campus Bio-Medico (1) · H. Lundbeck A/S (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Medical University of Vienna (1) · The Cleveland Clinic (1)
United States (20) · Finland (11) · Poland (11) · Spain (11) · Israel (10) · Canada (9) · Italy (9) · Germany (8) · Japan (7) · Netherlands (7) · Czechia (5) · United Kingdom (5) · Russia (4) · Sweden (4) · Australia (3)
Takehisa Matsumaru (3) · Carolyn A Bernstein, MD (1) · Christoph J Schankin, Prof (1) · Gregor Broessner, Prof (1) · Howard B Goldman, MD (1) · James F Meschia (1) · Katherine Hutcheson, BA,MS,PHD (1) · Yasuhiko Fukuta, PhD (1)
PMID 34819017, PMID 35331009, PMID 36038833, PMID 28862758, PMID 29722276, PMID 30120138, PMID 33413075, PMID 35139816, PMID 39221611, PMID 26432181, PMID 26432182, PMID 29171818, PMID 29800211, PMID 30450545, PMID 31427046, PMID 31675102, PMID 31752521, PMID 32747522, PMID 32887548, PMID 32913018, PMID 32958075, PMID 33863272, PMID 33990144, PMID 34246226, PMID 34687446, PMID 34922436, PMID 35302681, PMID 40323613, PMID 41534042, PMID 42616035
2019 (4), 2015 (3), 2016 (3), 2017 (1)